We have 4 of 142 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Pirtobrutinib and CAR T-cell therapy and CAR T-cell therapy have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors.
This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
The prevalence of CAR-positive T cells in patient-derived tissue sections, observed metabolic and proliferative shifts in the tumor and its microenvironment, and immune checkpoint analysis provide insights into post-CAR T secondary cancers and highlight tools that may guide future targeted therapies.
A trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain with overall response rate was 50%, including complete responses in 83% of lymphoma patients, and one-year overall survival rate was 61%, with durable remissions observed in lymphoma.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
